Lee M P, Reeves C, Schmitt A, Su K, Connors T D, Hu R J, Brandenburg S, Lee M J, Miller G, Feinberg A P
Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA.
Cancer Res. 1998 Sep 15;58(18):4155-9.
We previously reported the isolation of a 2.5 Mb tumor-suppressing subchromosomal transferable fragment (STF) from 11p15.5 and the identification of nine known genes and four novel genes within this STF. We now report the isolation of a fifth novel cDNA, tumor-suppressing STF cDNA 5, designated TSSC5, located within the STF. TSSC5 encodes a predicted protein of 424 amino acids. Sequence analysis suggests that TSSC5 is a membrane protein with 10 transmembrane segments, and it is located between two imprinted genes, p57KIP2 and TSSC3. Northern blot hybridization revealed a 1.6-kb transcript in multiple adult tissues and in fetal liver and kidney, consistent with a potential role in embryonal tumors. We also found that TSSC5 is imprinted with preferential expression from the maternal chromosome. Reverse transcription-PCR analysis of TSSC5 revealed frequent occurrence of aberrant RNA splicing, which deleted exons 4, 5, and 6 in Wilms' tumors. Mutational analysis of TSSC5 by direct DNA sequencing of exons revealed a base substitution of G1120A in a Wilms' tumor, matched normal kidney, and the patient's mother, changed Arg at codon 309 to Gln. The G1120A substitution thus represents either a rare polymorphism or a tumor-predisposing mutation, because the mutant allele was of maternal origin and preferentially expressed in the patient's tissue. A second base substitution, C892T, was found in a lung cancer, changing Ser at codon 233 to Phe. This substitution was absent from the matched normal tissue and thus represented a somatic mutation. We also found loss of heterozygosity in the lung cancer, suggesting that TSSC5 may be a conventional tumor suppressor gene in the adult human lung and an imprinted tumor suppressor gene in the fetal kidney.
我们之前报道了从11p15.5分离出一个2.5 Mb的肿瘤抑制亚染色体可转移片段(STF),并鉴定出该STF内的9个已知基因和4个新基因。我们现在报告分离出第五个新的cDNA,即肿瘤抑制STF cDNA 5,命名为TSSC5,位于该STF内。TSSC5编码一个预测的由424个氨基酸组成的蛋白质。序列分析表明,TSSC5是一种具有10个跨膜区段的膜蛋白,它位于两个印记基因p57KIP2和TSSC3之间。Northern印迹杂交显示在多种成人组织以及胎儿肝脏和肾脏中有一个1.6 kb的转录本,这与它在胚胎肿瘤中的潜在作用一致。我们还发现TSSC5是印记基因,母源染色体优先表达。对TSSC5的逆转录 - PCR分析显示,在肾母细胞瘤中频繁出现异常RNA剪接,导致外显子4、5和6缺失。通过对外显子直接DNA测序对TSSC5进行突变分析,发现在一个肾母细胞瘤、配对的正常肾脏以及患者母亲中存在G1120A的碱基替换,使密码子309处的精氨酸变为谷氨酰胺。因此,G1120A替换要么代表一种罕见的多态性,要么代表一种肿瘤易感突变,因为突变等位基因来自母源且在患者组织中优先表达。在一个肺癌中发现了第二个碱基替换C892T,使密码子233处的丝氨酸变为苯丙氨酸。该替换在配对的正常组织中不存在,因此代表一个体细胞突变。我们还在肺癌中发现了杂合性缺失,提示TSSC5可能是成人人类肺癌中的一个传统肿瘤抑制基因,以及胎儿肾脏中的一个印记肿瘤抑制基因。